



Yaupon Therapeutics is a privately-held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. Headquartered in Radnor, PA, the company employs 25 people and has in-house expertise in all facets of research and development.

The company's business philosophy is to build a highly capital efficient organization that leverages the National Institutes of Health (NIH) competitive grant system to offset research expenses and to validate its technology. This model emphasizes strong academic collaborations that lead to the licensing and development of unique products with proof of principle and millions of academic research dollars behind them. Yaupon currently has three products in development, with its most advanced program for cutaneous lymphoma in a pivotal study expected to be completed in mid 2010, with NDA filing anticipated shortly thereafter.

To date, Yaupon has received more than \$15 million in government support and more than \$20 million in venture capital investments. Investors include: Ben Franklin Technology Partners of Southeastern Pennsylvania, BioAdvance, Osage Venture Partners, Palo Alto Venture Investors, TDH/Midcoast Capital, and Vivo Ventures.

"Pennsylvania has been a remarkable place for a company like Yaupon to grow. There is a unique blend of both early-stage and growth capital in Pennsylvania, with pharmaceutical/biotech expertise perhaps being the regions greatest asset", said Robert J. Alonso, president and chief executive officer.

Product Pipeline

Clearazide™

Clearazide™ is a topically-delivered cytotoxic agent for treating cutaneous T-cell lymphoma - mycosis fungoides (CTCL-MF), psoriasis, and alopecia areata. It has been granted orphan drug designation for

treating CTCL-MF and is currently in pivotal clinical studies for this indication.

Clearazide™ works by suppressing T-cell proliferation, thereby reducing or clearing skin lesions associated with CTCL-MF. Yaupon is currently working with 13 of the top dermatological cancer centers in the U.S. and has received an FDA grant to support clinical activities. Upon FDA approval, Clearazide™ will be the first topical cytotoxic agent for treating this orphan disease, which affects roughly 60,000 patients in the U.S., Japan and EU. It has also demonstrated activity in other T-cell proliferating diseases such as psoriasis and alopecia areata.

Lobeline

Lobeline is a dopamine-modulating agent for the treatment of methamphetamine addiction and Attention Deficit Hyperactivity Disorder. It is currently in phase 2 clinical testing for both indications. Lobeline has the ability to modulate overactive dopamine production caused by disease or through the use of drugs of abuse. Yaupon is working through a partnership with the NIH to develop lobeline as the first pharmacological treatment for methamphetamine addiction, which is the fastest growing drug of abuse in the U.S.

YT-1006

YT-1006 is an NMDA antagonist for the treatment of neuropathic pain that eliminates classic NMDA side-effects through a unique stereochemistry approach. It is a unique NMDA antagonist in that has been shown to have a wide therapeutic index. In animal models of neuropathic pain, YT-1006 demonstrated very good analgesic activity, while toxicological experiments exhibited no observed side-effects in the efficacy dose range. Yaupon has received significant funding from the NIH through a competitive SBIR grant that will lead to a phase 1 study in 2010.

Other Products

Yaupon has other product programs in the pipeline focused on dermatological and central nervous system diseases. One program is a topically delivered plant-based extract that is being studied for various skin inflammatory conditions. This product has a unique mechanism of action that interrupts the inflammatory cascade. Yaupon expects to file an IND for this drug substance in 2010. Other programs include efforts in Tourette syndrome, movement disorders, addiction, and mental illness.